Psychiatric Medication, Practically

Why the ADHD Medication Shortage Keeps Going

Save

Rising demand for ADHD prescriptions, federal production quotas on Schedule II stimulants, and ongoing manufacturing constraints are combining to keep Adderall and its generics on the FDA's shortage list years after it first appeared [1]. No single cause explains it, and no single fix ends it quickly.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

The Short Answer

Three forces are combining to keep this shortage going: more people are being prescribed stimulant medications than in past years, federal quotas cap how much of the raw controlled-substance ingredient manufacturers can use annually, and manufacturing capacity hasn't consistently kept pace with either factor. The FDA has kept several Adderall formulations and generics on its official shortage list for an extended stretch, tracking the specific products and reasons behind each listing 1. None of these three pressures is simple to fix on its own, and they interact — quotas set a ceiling on supply while demand keeps pushing against that ceiling, so even modest demand growth can turn into a persistent gap. Understanding the mechanics doesn't make the wait shorter, but it does explain why this hasn't resolved the way a typical drug shortage might.

What's Driving the Demand Side?

Diagnosis rates for ADHD, particularly among adults, have climbed substantially over the past decade, and telehealth expanded access to prescribers in ways that made getting evaluated and treated considerably easier than it used to be. Temporary DEA flexibilities extended the ability to prescribe controlled substances like stimulants through telehealth without requiring an in-person visit first, which broadened who could realistically start treatment 2. More prescriptions written each month means more total stimulant medication needs to move through the same manufacturing and distribution system that existed before demand rose. None of this means the growth in diagnosis or treatment is a problem — expanded access to care is generally a good thing — but it does mean the supply side had to catch up to a bigger number than it was built for.

What's Limiting the Supply Side?

Manufacturing controlled substances involves more regulatory steps than manufacturing most other medications, and any disruption at one manufacturer's facility — a staffing issue, an ingredient delay, a quality hold — can ripple across the supply for weeks or months. Generic manufacturers, who produce most of the Adderall supply, tend to operate on thinner margins than brand-name manufacturers, which leaves less room to absorb a sudden spike in demand or an unplanned production gap. The FDA's shortage database tracks these specific reasons product by product, and manufacturing delay is one of the most commonly cited causes across stimulant listings 1. Generic and brand-name versions of the same drug are not always affected equally, which is part of why one pharmacy might have a generic in stock while a nearby one only has brand, or the reverse.

What Role Do DEA Production Quotas Play?

Schedule II controlled substances, including the active ingredients in Adderall and other stimulants, are subject to annual production quotas under federal controlled-substance regulation, which cap the total amount manufacturers are allowed to produce regardless of how much demand rises 3. Manufacturers cannot simply ramp up production past their allocated quota even when a shortage is actively happening, since going over requires additional federal approval that takes time to secure. This is part of why the shortage hasn't resolved the way a shortage of a non-controlled generic drug typically would — normal market signals that would usually prompt more production run into a hard regulatory ceiling. Quota adjustments do happen, but they tend to lag behind the demand growth that triggered the shortage in the first place, which keeps the gap open longer than many people expect.

Is the Shortage Getting Better?

Availability has shifted unevenly rather than resolving cleanly — some months and some formulations have been easier to find than others 1. The FDA's searchable shortage database tracks these status changes as they happen, rather than issuing one final all-clear 4. Checking the current shortage status for a specific medication is more useful than assuming things are either fully fixed or fully stuck, since the picture keeps moving. A prescriber conversation about switch options can be worth having even before a specific pharmacy runs dry, just to have a plan ready. Whatever the current status, this is a logistics problem with real solutions, not a sign that treatment itself has failed.

Common questions

Not always — brand and generic manufacturers face different production pressures, so one is sometimes easier to find than the other at a given moment, though brand-name typically costs more out of pocket.

Yes — the shortage has touched multiple stimulant medications at different times, not just Adderall, since they share some of the same regulatory and manufacturing pressures.

Usually, as long as the new pharmacy is in-network; checking an insurer's app or calling ahead for nearby in-network pharmacies before a resend goes out can save a surprise bill.

Some pharmacy chains offer text or app alerts for out-of-stock medications, and asking a pharmacist directly whether that service exists locally is worth doing if repeated calling has gotten old.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

If things feel heavy, a person is available anytime — call or text 988.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

If going without medication starts to feel unsafe

  • —Struggling to function safely at work, school, or while driving without your medication
  • —Noticing a sharp drop in mood, focus, or safety that worries you or people close to you
  • —Having thoughts of hopelessness or self-harm during a gap in treatment
  • —A gap that's stretched well beyond what your prescriber expected with no resolution in sight

This article is general information, not medical or legal advice, and shortage conditions change over time and vary by location. If you're having thoughts of suicide or self-harm, the 988 Suicide & Crisis Lifeline is free, confidential, and available 24/7 by call or text at 988.

References

  1. 1.U.S. Food and Drug Administration (2025). Drug Shortages. U.S. Food and Drug Administration (FDA). link ✓psych-med-shortagemedication-accessstimulant-shortage
  2. 2.Drug Enforcement Administration (2025). Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Federal Register. link ✓dea-telemedicinecontrolled-substance-prescribingtelehealth-policy
  3. 3.Substance Abuse and Mental Health Services Administration (2025). Substance Use Disorders: Statutes, Regulations, and Guidelines. Substance Abuse and Mental Health Services Administration (SAMHSA). link ✓moud-regulationtelehealth-prescribingcontrolled-substance-policy
  4. 4.U.S. Food and Drug Administration (2025). FDA Drug Shortages (searchable database). U.S. Food and Drug Administration (FDA). link ✓psych-med-shortageadderall-shortagemedication-access

4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library